List of redirects

Jump to navigation Jump to search

Showing below up to 50 results in range #55,001 to #55,050.

View ( | ) (20 | 50 | 100 | 250 | 500)

  1. Tyrer sulfonation process → Aromatic sulfonation
  2. Tyrosinaemia → Tyrosinemia
  3. Tyrosinaemia type 1 → Tyrosinemia
  4. Tyrosinaemia type 2 → Hanhart syndrome
  5. Tyrosine-kinase → Tyrosine kinase
  6. Tyrosine 3-monooxygenase → Tyrosine hydroxylase
  7. Tyrosine aminotransferase deficiency → Hanhart syndrome
  8. Tyrosine hydroxylase inhibitor → Tyrosine hydroxylase
  9. Tyrosine kinase inhibitor → Protein kinase inhibitor
  10. Tyrosine kinase inhibitors → Protein kinase inhibitor
  11. Tyrosine kinases → Tyrosine kinase
  12. Tyrosine phosphatase → Protein tyrosine phosphatase
  13. Tyrosinemia type 1 → Tyrosinemia
  14. Tyrosines → Tyrosine
  15. Tysabri → Natalizumab
  16. Tyzeka → Telbivudine
  17. Tzanck smear → Tzanck test
  18. Tæniæ → Taenia coli
  19. Tγ-lymphoproliferative disorder → T-cell large granular lymphocyte leukemia
  20. U-235 → Uranium-235
  21. U-Tri-Lone → Triamcinolone
  22. U.S. Agency for International Development → United States Agency for International Development
  23. U.S. Department of Agriculture → United States Department of Agriculture
  24. U.S. Department of Health and Human Services → United States Department of Health and Human Services
  25. U.S. Food and Drug Administration → Food and Drug Administration
  26. U.S. National Institutes of Health → National Institutes of Health
  27. U.S. National Library of Medicine → United States National Library of Medicine
  28. U.S. Public Health Service → United states public health service
  29. U.S. customary unit → United States customary units
  30. U.S. drug regulation → Regulation of therapeutic goods#United States
  31. U. urealyticum → Ureaplasma urealyticum
  32. U. urealyticum biovar 1 → Ureaplasma urealyticum
  33. U. urealyticum biovar 2 → Ureaplasma urealyticum
  34. U.parvum → Ureaplasma urealyticum
  35. U.urealyticum → Ureaplasma urealyticum
  36. U.urealyticum biovar 1 → Ureaplasma urealyticum
  37. U4EA → 4-Methyl-aminorex
  38. UA → Unstable angina / non ST elevation myocardial infarction
  39. UA/NSTEMI ACC/AHA guidelines for immediate management → Unstable angina / non ST elevation myocardial infarction ACC/AHA guidelines for immediate management
  40. UA/NSTEMI inhibitors of RAS → Unstable angina / non ST elevation myocardial infarction inhibitors of RAS
  41. UA/NSTEMI long-term medical therapy and secondary prevention ACC/AHA guidelines Nonsteroidal Anti-Inflammatory Drugs → Unstable angina / non ST elevation myocardial infarction long-term medical therapy and secondary prevention ACC/AHA guidelines nonsteroidal anti-inflammatory drugs
  42. UA/NSTEMI long-term medical therapy and secondary prevention ACC/AHA guidelines antioxidant vitamins and folic acid → Unstable angina / non ST elevation myocardial infarction long-term medical therapy and secondary prevention ACC/AHA guidelines antioxidant vitamins and folic acid
  43. UA/NSTEMI long-term medical therapy and secondary prevention ACC/AHA guidelines depression → Unstable angina / non ST elevation myocardial infarction long-term medical therapy and secondary prevention ACC/AHA guidelines depression
  44. UA/NSTEMI long-term medical therapy and secondary prevention ACC/AHA guidelines for CCB → Unstable angina / non ST elevation myocardial infarction long-term medical therapy and secondary prevention ACC/AHA guidelines for calcium channel blockers
  45. UA/NSTEMI long-term medical therapy and secondary prevention ACC/AHA guidelines for Physical Activity → Unstable angina / non ST elevation myocardial infarction long-term medical therapy and secondary prevention ACC/AHA guidelines for physical activity
  46. UA/NSTEMI long-term medical therapy and secondary prevention ACC/AHA guidelines for antiplatelet therapy → Unstable angina / non ST elevation myocardial infarction long-term medical therapy and secondary prevention ACC/AHA guidelines for antiplatelet therapy
  47. UA/NSTEMI long-term medical therapy and secondary prevention ACC/AHA guidelines for beta blockers → Unstable angina / non ST elevation myocardial infarction long-term medical therapy and secondary prevention ACC/AHA guidelines for beta blockers
  48. UA/NSTEMI long-term medical therapy and secondary prevention ACC/AHA guidelines for blood pressure control → Unstable angina / non ST elevation myocardial infarction long-term medical therapy and secondary prevention ACC/AHA guidelines for blood pressure control
  49. UA/NSTEMI long-term medical therapy and secondary prevention ACC/AHA guidelines for diabetes mellitus → Unstable angina / non ST elevation myocardial infarction long-term medical therapy and secondary prevention ACC/AHA guidelines for diabetes mellitus
  50. UA/NSTEMI long-term medical therapy and secondary prevention ACC/AHA guidelines for inhibitors of the RAS → Unstable angina / non ST elevation myocardial infarction long-term medical therapy and secondary prevention ACC/AHA guidelines for inhibitors of the RAS

View ( | ) (20 | 50 | 100 | 250 | 500)

Retrieved from "https://www.wikidoc.org/index.php/Special:ListRedirects"